Comparative Pharmacology
Head-to-head clinical analysis: ANDROGEL versus ANDROID 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROGEL versus ANDROID 10.
ANDROGEL vs ANDROID 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
None Documented
None Documented
The terminal elimination half-life of testosterone from AndroGel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Category C
Category C
Androgen
Androgen